Resistens hos lakselus
Veterinærinsituttet overvåker følsomhet og resistens hos lakselus.
Formål med programmet er å gi en best mulig beskrivelse av lakselus sin følsomhet mot legemidler, samt gi råd om bruk av legemidler for å kontrollere lakselus hos oppdrettsfisk. Fra 2019 har formålet også vært å undersøke om det er forskjell i ferskvannstoleranse mellom lus fra områder det ferskvann er lite eller mer brukt til avlusning.
2022
The number of prescriptions for anti-salmon lice medicines were the same in 2022 as in 2021. The number of prescriptions has been relatively stable since 2017. This is in contrast to the period 2014 to 2017, during which the number decreased by 78 percent.
In 2021, for the first time in more than two decades, a new anti-salmon lice medicine from a new substance class was approved in Norway. The use of this agent, with the active substance imidacloprid, was moderate in both 2021 and 2022, with 29 and 54 prescriptions respectively.
The level of resistance seen in salmon lice towards most anti-salmon medicines remained high in 2022.
Last ned rapporten
Eldre rapporter
- Salmon lice - resistance to chemotherapeutants 2021 (pdf 2mb)
- Salmon lice - resistance to chemotherapeutants 2020 (pdf 2mb)
- Salmon lice - resistance to chemotherapeutants 2019 (pdf 2mb)
- Salmon lice - resistance to chemotherapeutants 2018 (pdf 2mb)
- Salmon lice - resistance to chemotherapeutants 2017 (pdf 818kb)
- Salmon lice - resistance to chemotherapeutants 2016 (pdf 1mb)
- Salmon lice - resistance to chemotherapeutants 2015 (pdf 2mb)
- Salmon lice - resistance to chemotherapeutants 2014 (pdf 769kb)
- Salmon lice - resistance to chemotherapeutants 2013 (pdf 2mb)